Lipid formulations of amphotericin B: Clinical perspectives for the management of invasive fungal infections in children with cancer

Klinische Padiatrie

Volumn 210, Issue 4, 1998, Pages 264-273

  Groll, Andreas H ^a   Müller, Frank Michael C ^a   Piscitelli, Stephen C ^b   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Amphotericin B; Antifungal agents; Cancer; Mycoses

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX;

ANTIFUNGAL ACTIVITY; CHILD; CHILDHOOD CANCER; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; INFECTIOUS COMPLICATION; MYCOSIS; REVIEW;

EID: 0031829724     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1043890     Document Type: Review

References (86)

1. Adedoyin, A., J. F. Bernardo, C. E. Swenson et al.: Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob. Agents Chemother. 41 (1997) 2201-2208
2. Amantea, M. A., R. A. Bowden, A. Forrest et al.: Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob. Agents Chemother. 39 (1995) 2042-2047
3. Amphotericin B Lipid Complex Injection (Abelcet™) package insert. SEQUUS Pharmaceuticals, Menlo Park, CA 1996
4. Anaissie, E., H. Kantarjian, J. Ro et al.: The emerging role of Fusarium infections in patients with cancer. Medicine (Baltimore) 67 (1988) 77-83
5. Anaissie, E.: Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin. Infect. Dis. 14. suppl D (1992) S43-S53
6. Anaissie, E. J., M. White, O. Uzun et al.: Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: a prospective, randomized, multicenter trial. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, abstract LM 21, p. 330. American Society for Microbiology, Washington, DC 1995
7. Arning, M., K. O. Kliche, A. H. Heer-Sonderhoff et al.: Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses 38 (1995) 459-465
8. Arning, M., R.E .Scharf: Prevention of amphotericin B induced nephrotoxicity by loading with sodium-chloride: A report of 1291 days of treatment with amphotericin B without renal failure. Klin. Wochenschr. 67 (1989) 1020-1028
9. Atkinson Jr, A. J., J. E. Bennett: Amphotericin B pharmacokinetics in humans. Antimicrob. Agents Chemother. 13 (1978) 271-276
10. Ayestaran, A., R. M. Lopez, J. B. Montero et al.: Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia. Antimicrob. Agents Chemother. 40 (1996) 609-612
11. Barton, E., H. Zinnes, R. A. Moe et al.: Studies on a new solubilized preparation of amphotericin B. In: Antibiotics Annual, 1957-1958. pp. 53-57. Medical Encyclopedia. Inc., New York, NY 1958
12. Benson, J. M., M. C. Nahata: Pharmacokinetics of amphotericin B in children. Antimicrob. Agents Chemother. 33 (1989) 1989-1993
13. Bodey, G. P.: The emergence of fungi as major hospital pathogens. J. Hosp. Infect. 11, suppl A (1988) 411-426
14. Bowden, R. A., M. Cays, T. Gooley et al.: Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant. J. Infect. Dis. 173 (1996) 1208-1215
15. Butler, W. T.: Pharmacology, toxicology and therapeutic usefulness of amphotericin B. JAMA 195 (1966) 127-131
16. Caillot, D., G. Reny, E. Solary et al.: A controlled trial of the tolerance of amphotericin B infused in dextrose or Intralipid in patients with hematological malignancies. J. Antimicrob. Chemother. 33 (1994) 603-613
17. Caillot, D.: Interest of amphotericin B infused into Intralipid for the treatment of candidemia in neutropenic patients: a report of 36 cases. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract J48, p.227. American Society for Microbiology, Washington, DC 1996
18. Chavanet, P., M. Duong, M. Biusson et al.: In vivo activity and tolerance of conventional formulation versus fat emulsion formulation of amphotericin B in experimental disseminated candidiasis in neutropenic rabbits. J. Antimicrob. Chemother. 39 (1997) 427-430
19. Chavanet, P. Y., I. Garry, N. Charlier et al.: Trial of glucose versus fat emulsion in preparation of amphotericin B for use in HIV infected patients with candidiasis. Br. Med. J. 305 (1992) 921-925
20. Coker, R. J., M. Viviani, B. G. Gazzard et al.: Treatment of cryptococcosis with liposomal amphotericin B in 23 patients with AIDS. AIDS 7 (1993) 829-835
21. Daneshmend, T. K., D. W. Warnock: Clinical pharmacokinetics of systemic antifungal drugs. Clin. Pharmacokinetics 8 (1983) 17-42
22. Denning, D. W., D. A. Stevens: Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev. Infect. Dis. 12 (1990) 1147-1201
23. Dornbusch, H. J., C. E. Urban, H. Pinter et al.: Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome™), granulocyte colony-stimulating factor, and surgery: report of five cases. Pediatr. Hematol. Oncol. 12 (1995) 577-586
24. Gerkens, J. F., R. A. Branch: The influence of sodium status and furosemide on canine acute amphotericin B nephrotoxicity. J. Pharmacol. Exp. Ther. 214 (1980) 306-311
25. Gold, W., H. A. Stout, I. F. Pagona et al.: Amphotericins A and B, antifungal antibiotics produced by a streptomycete. I. In vitro studies. In: Antibiotics Annual, 1955-1956, pp. 579-586. Medical Encyclopedia, Inc., New York, NY 1955
26. Groll, A. H., G. Just-Nuebling, M. Kurz et al.: Fluconazole vs. nystatin in the prevention of Candida infections in children undergoing remission induction or consolidation chemotherapy for cancer. J. Antimicrob. Chemother. 40 (1997) 855-862
27. Groll, A. H., P. M. Shah, C. Mentzel et al.: Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J. Infect. 33 (1996) 23-32
28. Groll, A. H., S. C. Piscitelli, T. J. Walsh: Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. Pharmacol. 44 (1998) 343-500
29. Groll, A. H., T. J. Walsh: Potential new antifungal agents. Curr. Opin. Infect. Dis. 10 (1997) 449-458
30. Heidemann, H. T., J. F. Gerkens, W. A. Spickard et al.: Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am. J. Med. 75 (1983) 476-481
31. Heinemann, V., D. Bosse, U. Jehn et al.: Pharmacokinetics of liposomal amphotericin B (AmBisome™) in critically ill patients. Antimicrob. Agents Chemother. 41 (1997) 1275-1280
32. Heinemann, V., B. Kaehny, U. Jehn et al.: Serum pharmacology of amphotericin B applied in lipid emulsion. Antimicrob. Agents Chemother. 41 (1997) 728-732
33. Herbrecht, R., V. Letscher, E. Andres et al.: Zygomycosis treated with amphotericin B colloidal dispersion: a review of 22 cases. Blood 88,-suppl.1 (1996) 502a
34. Herbrecht, R.: Safety of amphotericin B colloidal dispersion. Eur. J. Clin. Microbiol. Infect. Dis. 16 (1997) 74-80
35. Hiemenz, J. W., J. Lister, E. J. Anaissie et al.: Emergency use of amphotericin B lipid complex (ABLC) in the treatment of patients with aspergillosis: historical control comparison with amphotericin B. Blood 86, suppl 1 (1995) 849a
36. Hiemenz, J. W., T. J. Walsh: Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22, suppl.2 (1996) S133-S144
37. Janknegt, R., S. deMarie, I. A. J. M. Bakker-Woudenberg et al.: Liposomal and lipid formulations of amphotericin B. clinical pharmacokinetics. Clin. Pharmacokinet. 23 (1992) 279-291
38. Joly, V., P. Aubry, A. Ndayiragide et al.: Randomized comparison of amphotericin deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis. Clin. Infect. Dis. 23 (1996) 556-562
39. Joly, V., C. Geoffray, J. Reynes et al.: Amphotericin B in lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients. J. Antimicrob. Chemother. 38 (1996) 117-126
40. Kan, V. L., J. E. Bennet, M. A. Amantea et al.: Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B deoxycholate in healthy male volunteers. J. Infect. Dis. 164 (1991) 418-421
41. Kirsh, R., R. Goldstein, J. Tarloff et al.: An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J. Infect. Dis. 158 (1988) 1065-1070
42. Kline, S., T. A. Larsen, L. Fieber et al.: Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex. Clin. Infect. Dis. 21 (1995) 1154-1158
43. Leenders, A. C. A. P., P. Reiss, P. Portegies et al.: Liposomal amphotericin B (AmBisome™) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 11 (1997) 1463-1471
44. Lopez, R. M., A. Ayestaran, L. Pou et al.: Stability of amphotericin B in an extemporaneously prepared i.v. fat emulsion. Amer. J. Health Syst. Pharm. 53 (1996) 2724-2727.
45. Mehta, J., S. Kelsey, P. Chou et al.: Amphotericin B lipid complex (-ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematological malignancies. Bone Marrow Transplant. 20 (1997) 39-43
46. Meunier, F., H. G. Prentice, O. Ringden: Liposomal amphotericin B (AmBisome™): safety data from a phase II/III clinical trial. J. Antimicrob. Chemother. 28, suppl. B (1991) 83-91
47. Meyers, J. D.: Fungal infections in bone marrow transplant patients. Semin. Oncol. 17, suppl 6 (1990) 10-13
48. Mills, W., R. Chopra, D. C. Linch et al.: Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: A single-center experience of 133 episodes in 116 patients. Br. J. Haematol. 86 (1994) 754-760
49. Moreau, P., N. Milpied, N. Fayette et al.: Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J. Antimicrob. Chemother. 30 (1992) 535-541
50. Mott, S. H., R. J. Packer, L. G. Vezina et al.: Encephalopathy with parkinsonian features in children following bone marrow transplantation and high dose amphotericin B. Ann. Neurol. 37 (1995) 810-814
51. Ng , T. T. C., D. W. Denning: Liposomal amphotericin B (AmBisome™) therapy in invasive fungal infections: evaluation of United Kingdom compassionate use data. Arch. Intern. Med. 155 (1995) 1093-1098
52. Nguyen, M. H., J. E. Peacock, A. J. Morris et al.: The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100 (1996) 617-623
53. Noskin, G. A., G. Coffey, M. Gurwith: Treatment of candidemia with amphotericin B colloidal dispersion. In: Abstracts of the 34th Annual Meeting of the Infectious Disease Society of America, abstract 78, page 50. Infectious Disease Society of America, Washington, DC 1996
54. Oppenheim, B. A., R. Herbrecht, S. Kusne: The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin. Infect. Dis. 21 (1995) 1145-1153
55. Pascual, B., A. Ayestaran, J. B. Montoro et al.: Administration of lipid emulsion versus conventional amphotericin B in patients with neutropenia. Ann. Pharmacother. 29 (1995) 1197-1201
56. Pasic, S., L. Flannagan, A. J. Cant: Liposomal amphotericin B (AmBisome™) is safe in bone marrow transplantation for primary immunodeficiency. Bone Marrow Transplant. 19 (1997) 1229-1232
57. Pizzo, P. A., K. J. Robichaud, F. A. Gill et al.: Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Amer. J. Med. 72 (1982) 101-111
58. Prentice, H. G., I. M. Hann, R. Herbrecht et al.: A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br. J. Haematol. 98 (1997) 711-718
59. Ranchere, J. Y., J. F. Latour, C. Fuhrmann et al.: Amphotericin B Intralipid formulation: stability and particle size. J. Antimicrob. Chemother. 37 (1996) 1165-1169
60. Reynolds, E. S., Z. M. Tomkiewicz, G. J. Dammin: The renal lesion related to amphotericin B treatment for coccidioidomycosis. Med. Clin. North. Amer. 47 (1963) 1149-1154
61. Rinaldi, M. G.: Problems in the diagnosis of invasive fungal infections. Rev. Infect. Dis. 13 (1991) 493-495.
62. Ringden, O.: Clinical use of AmBisome™™ with special emphasis on experience in children. Bone Marrow Transplant. 12, suppl. 4 (1993) S149-S150
63. Ringden, O., E. Andstroem, M. Remberger et al.: Safety of liposomal amphotericin B (AmBisome™) in 187 transplant recipients treated with cyclosporin. Bone Marrow Transplant. 14, suppl. 5 (1994) S10-S14
64. Ringden, O., F. Meunier, J. Tollemar et al.: Efficacy of amphotericin B encapsulated in liposome (AmBisome™) in the treatment of invasive fungal infections in immunocompromised patients. J. Antimicrob. Chemother. 28 suppl. B (1991) 73-82
65. Sawaya, B. P., J. P. Briggs, J. Schnermann: Amphotericin B nephrotoxicity: The adverse consequences of altered membrane properties. J. Amer. Soc. Nephrol. 6 (1995) 154-164
66. Schoeffski, P., R. Wunder, D. Petersen et al.: Amphotericin B in Intralipid: No evidence for improved toxicity profile. Results of a randomized phase II-trial in neutropenic patients. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, p. 287, Abstr. LM36, American Society for Microbiology, Washington, DC 1995
67. Shadkhan, Y., E. Segal, A. Bor et al.: The use of commercially available lipid emulsions for the preparation of amphotericin B-lipid admixtures. J. Antimicrob. Chemother. 39 (1996) 655-658
68. Sharkey, P. K., J. R. Graybill, E. S. Johnson et al.: Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 22 (1996) 315-321
69. Sievers, T. M., B. M. Kubak, A. Wong-Beringer: Safety and efficacy of Intralipid emulsions of amphotericin B. J. Antimicrob. Chemother. 38 (1996) 333-347
70. Sorkine, P., H. Nagar, A. Weinbroum et al.: Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients. Crit. Care Med. 24 (1996) 1311-1315
71. Starke, J. R., O. Mason, W. G. Kramer et al.: Pharmacokinetics of amphotericin B in infants and children. J. Infect. Dis. 155 (1987) 766-774
72. Tollemar, J., O. Ringden, S. Andersson et al.: Randomized double-blind study of liposomal amphotericin B (AmBisome™) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant. 12 (1993) 577-582
73. Trissel, L. A.: Amphotericin B does not mix with fat emulsion. Amer. J.-Health Syst. Pharm. 52 (1995) 1463-1464
74. Vartivarian, S. E., E. J. Anaissie, G. P. Bodey: Emerging fungal pathogens in immunocompromized patients: classification, diagnosis, management. Clin. Infect. Dis. 1 7suppl. 2 (1993) 487-491
75. Walsh, T. J., C. Gonzalez, C. Lyman et al.: Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv. Pediatr. Infect. Dis. 11 (1996) 187-290
76. Walsh, T. J., D. Bodensteiner, J. Hiemenz et al.: A randomized, double-blind trial of AmBisome™ (liposomal amphotericin B) versus amphotericin B in the empirical treatment of persistently febrile neutropenic patients. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, abstract LM-90, p.381. American Society for Microbiology, Washington, DC 1997
77. Walsh, T. J., G. P. Melcher, M. G. Rinaldi et al.: Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J. Clin. Microbiol. 28 (1990) 1616-1622
78. Walsh, T. J., I. Bekersky, V. Teldandi et al.: Pharmacokinetics of AmBisome™ in persistently febrile neutropenic patients receiving empirical antifungal therapy. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, p. 13, Abstr. A11, American Society for Microbiology, Washington, DC 1995
79. Walsh, T. J., J. W. Hiemenz, N. Seibel et al.: Amphotericin B lipid complex in invasive fungal infections: analysis of safety and efficacy in 556 cases. In: Abstracts of the 13th Congress of the International Society for Human and Animal Mycology, p.221, Abstr. P-571. International Society for Human and Animal Mycology, Parma, Italy 1997
80. Walsh, T. J., P. Whitcomb, S. Piscitelli et al.: Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob. Agents. Chemother. 41 (1997) 1944-1948
81. Wasan, K. M., M. G. Rosenblum, L. Cheung et al.: Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrob. Agents Chemother. 38 (1994) 223-227
82. White, M. H., E. J. Anaissie, S. Kusne et al.: Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin. Infect. Dis. 24 (1997) 635-642
83. White, M. H., R. A. Bowden, E. Sandler et al.: Amphotericin B colloidal dispersion (ABCD) vs. amphotericin B in the empiric treatment of febrile neutropenic patients. Blood 88 suppl. 1 (1996) 302a
84. Wingard, J. R.: Efficacy of amphotericin B lipid complex injection (-ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant. 19 (1997) 343-347
85. Wright, D. G., K. J. Robichaud, P. A. Pizzo et al.: Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N. Engl. J. Med. 304 (1981) 1185-1189
86. Zoubek, A., W. Emminger, W. Emminger-Schmidmeier et al.: Conventional vs.liposomal amphotericin B in immunosuppressed children. Ped. Hematol. Oncol. 9 (1992) 187-190